Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 19/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2695203 | 1.00 | TRPV1 (0.56) | TRPV1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2688751 | 0.79 | TRPV1 (0.59) | TRPV1 | |
| SCHEMBL2687735 | 0.79 | TRPV1 (0.59) | TRPV1 | |
| SCHEMBL2687740 | 0.79 | TRPV1 (0.59) | TRPV1 | |
| SCHEMBL2688135 | 0.79 | TRPV1 (0.60) | TRPV1 | |
| SCHEMBL2689448 | 0.79 | TRPV1 (0.60) | TRPV1 | |
| SCHEMBL2688130 | 0.77 | TRPV1 (0.72) | TRPV1 | |
| SCHEMBL12982587 | 0.77 | TRPV1 (0.60) | TRPV1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2688102 | 0.76 | TRPV1 (0.59) | TRPV1 | |
| SCHEMBL2687484 | 0.76 | TRPV1 (0.54) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638015-A1 | SUBSTITUTED BICYCLIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2013-09-18 | — | — | EP | claimed |
| WO-2012062463-A1 | SUBSTITUTED BICYCLIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2012-05-18 | — | — | WO | claimed |
| US-20120115893-A1 | Substituted Bicyclic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2012-05-10 | — | — | US | claimed |
| EP-2638015-A1 | SUBSTITUTED BICYCLIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062463-A1 | SUBSTITUTED BICYCLIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2012-05-18 | — | — | WO | disclosed |
| US-20120115893-A1 | Substituted Bicyclic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115893-A1 | Substituted Bicyclic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | TRPV1, CNR1, CNR2 | TRPV1 1/4885MAPK13 2366/4885MAPK12 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.